July 1, 2024
You are here:  Home  >  Banking & Finance  >  Current Article

Arcutis reports Q3 loss, but first product revenue


Westlake Village-based Arcutis’ losses continue to mount, but in the third quarter of 2022 it recorded product revenue for the first time in its history. Arcutis, a biotechnology company focused on treating skin diseases, launched its first product, Zoryve, in August. Zoryve is a cream focused on the treatment of plaque psoriasis in adolescents and…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.